The NF-κB singling pathway as a target for Hepatocellular carcinoma (HCC) treatment

The NF-κB singling pathway as a target for Hepatocellular carcinoma (HCC) treatment
hossein bahrami moghaddam,^1,* reza kherdi,² Mohammad Amin Dehghani ,³ neda pakray,⁴ reza abooali,⁵
1. Medical Student, Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2. Medical Student, Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3. Medical Student, Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4. Medical Student, Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Introduction: Hepatocellular carcinoma (HCC) is globally one of the leading causes of mortality from cancer. The advanced HCC has still poor prognosis in spite of boosting multidisciplinary therapeutic strategies. Of the agents involved in the chronic inflammation and HCC development is nuclear factor κB (NF‐κB), whose singling pathway is capable of activating many cellular processes, such as cell expansion, survival, proliferation and vesicular transport, but being dysregulated in HCC
Methods: The search strategy was to find related articled in English on database of PubMed using keywords of HCC, NF-κB, NF-κB singling, NF-κB inhibitor, sorafenib, treatment
Results: NF-κB has been shown to be associated with hepatic injury, fibrosis and HCC, suggesting its targeted mechanism to inhibit and heal liver fibrosis and HCC. The NF-κB inhibition has both positive impacts and negative effects such as hepatocyte viability. Different anticancer agents and radiation can stimulate apoptosis and provoke anti-apoptotic proteins induced by NF-κB, decreasing the effectiveness of in vitro and in vivo treatment in HCC. One of the NF-κB inhibitors is sorafenib that decreases the expression of NF-κB-modulated anti-apoptotic proteins in HCC both in vitro and in vivo
Conclusion: Naturally occurring inhibitors are important in the NF-kB pathway, which have been recently studied to treat the cancer. Accordingly, the HCC prognosis can be promoted following the control of NF-κB activation through novel therapeutic target
Keywords: HCC, NF-κB, NF-κB singling, NF-κB inhibitor, sorafenib, treatment